01850nam a2200409 i 4500001001300000003000600013005001700019007001400036008004100050040004500091042000800136043001200144050002200156074001600178086002000194099002000214110008200234245013400316264007100450300002300521336002600544337002700570338003100597490007700628500002000705500003600725500002500761533010600786650005800892650005200950650005001002655003401052776013901086776013801225810005801363999001901421ocn976178012OCoLC20180416115119.0he bmb024bbca170316s2017    dcu     b    f000 0 eng c  aPTLbengerdacPTLdOCLCQdNTEdGPOdMvI  apcc  an-us---14aKF32b.E55 2016zd  a1008-D (MF)0 aY 1.1/8:114-672  aY 1.1/8:114-6721 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce,eauthor.10aDXM Abuse Prevention Act of 2015 :breport (to accompany H.R. 3250) (including cost estimate of the Congressional Budget Office). 1a[Washington, D.C.] :b[U.S. Government Publishing Office],c[2016]  a26 pages ;c24 cm.  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier1 aReport / 114th Congress, 2d session, House of Representatives ;v114-672  a"July 8, 2016."  aShipping list no.: 2016-0248-M.  aCRDP Program record.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2018]e1 microfiche : negative. 0aDextromethorphanxLaw and legislationzUnited States. 0aDrug abusexLaw and legislationzUnited States. 0aPharmacyxLaw and legislationzUnited States. 7aLegislative materials.2lcgft08iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce.tDXM Abuse Prevention Act of 2015w(OCoLC)95352523208iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce.tDXM Abuse Prevention Act of 2015w(OCoLC)9537988201 aUnited States.bCongress.bHouse.tReport ;v114-672.  c270694d270694